MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
AIkido Pharma Operating Income 2011-2026 | AIKI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income AIkido Pharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.5 M | -21.8 M | -14.3 M | -9.44 M | -6.55 M | -5.68 M | -6.87 M | -3.82 M | -8.55 M | -52 M | -30.6 M | -15.3 M | -3.47 M | -4.19 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.47 M | -52 M | -13.9 M |
Quarterly Operating Income AIkido Pharma
| 2025-Q3 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.6 M | - | -3.2 M | -2.74 M | -2.8 M | - | -3.1 M | -9.01 M | -3.83 M | - | -5.1 M | -2.3 M | -3.8 M | - | -1.78 M | -2.76 M | -2.32 M | - | -966 K | -1.79 M | -2.4 M | - | -902 K | -888 K | -713 K | - | -1.95 M | -1.26 M | -1.58 M | - | -959 K | -777 K | -969 K | - | -1.49 M | -1.62 M | -1.56 M | - | -1.96 M | -40.3 M | -4.12 M | - | -5.16 M | -11.6 M | -8.01 M | - | -9.32 M | -947 K | -911 K | - | -634 K | -669 K | -1.06 M | - | -789 K | -1.02 M | -1.11 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -634 K | -40.3 M | -3.53 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K |  USA |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 9.46 | 1.18 % | $ 139 M | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-704 M | $ 10.01 | -7.66 % | $ 647 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 211.38 | -0.9 % | $ 5 B |  Danmark |
 |
Aclaris Therapeutics
ACRS
|
-142 M | $ 2.62 | -9.2 % | $ 203 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 4.28 | -2.73 % | $ 9.31 B |  Israel |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 96.5 | -0.2 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 26.84 | 1.42 % | $ 1.3 B | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.81 | -3.21 % | $ 462 M | Britain |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-41.8 M | $ 0.85 | 3.22 % | $ 116 M | USA |
 |
Catalyst Biosciences
CBIO
|
-67.2 M | $ 11.08 | -0.05 % | $ 729 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
BioVie
BIVI
|
-18.1 M | $ 1.29 | -3.01 % | $ 1.91 M | USA |
 |
Axon Enterprise
AXON
|
58.5 M | $ 593.03 | 5.25 % | $ 44.9 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.9 | 4.69 % | $ 18.2 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 91.04 | -0.58 % | $ 96.9 B | Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 9.11 | 4.35 % | $ 1.48 B | Britain |
 |
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | USA |
 |
Cellectis S.A.
CLLS
|
-131 M | $ 4.56 | -5.1 % | $ 116 M | France |
 |
Biogen
BIIB
|
7.04 B | $ 174.34 | -1.96 % | $ 25.4 B | USA |
 |
Cellectar Biosciences
CLRB
|
-39 M | $ 3.39 | -2.31 % | $ 41.4 M | USA |
 |
Abeona Therapeutics
ABEO
|
-47.1 M | $ 5.23 | -1.6 % | $ 112 M | USA |